Filing Flows › Comparisons › SNY vs AZN
Sanofi vs AstraZeneca: SNY and AZN compared
Sanofi is the larger company: $14.4B of revenue in its latest quarter (Q3 2026) against $16.2B for AstraZeneca (Q3 2026). Sanofi is growing faster (+16% against +7% a year earlier). Sanofi is more profitable, with an operating margin of 30.1% against 27.1%.
Where the money goes: SNY and AZN
Sanofi (SNY) · Q3 2026
Sanofi, Q3 2026: revenue $14.4B (+16% year over year), operating margin 30.1%, net earnings $3.0B, operating cash flow $3.9B. The chart follows the revenue to costs, profit and cash.
AstraZeneca (AZN) · Q3 2026
AstraZeneca, Q3 2026: revenue $16.2B (+7% year over year), operating margin 27.1%, net earnings $3.1B, operating cash flow $5.8B. The chart follows the revenue to costs, profit and cash.
| Sanofi (SNY) | AstraZeneca (AZN) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $14.4B | $16.2B |
| Revenue growth, Y/Y | +16% | +7% |
| Gross margin | 80.3% | 81.8% |
| Operating margin | 30.1% | 27.1% |
| Net earnings | $3.0B | $3.1B |
| Net margin | 21.0% | 19.2% |
| Operating cash flow | $3.9B | $5.8B |
| Free cash flow | — | $5.1B |
Where the revenue comes from
AstraZeneca
- Oncology: $7.1B (44%)
- CVRM: $2.6B (16%)
- Farxiga: $1.6B (10%)
- Ultomiris: $1.4B (9%)
Questions
Which is bigger, Sanofi or AstraZeneca?
Sanofi is the larger company: $14.4B of revenue in its latest quarter (Q3 2026) against $16.2B for AstraZeneca (Q3 2026).
Is Sanofi or AstraZeneca growing faster?
Sanofi is growing faster (+16% against +7% a year earlier).
Which is more profitable, Sanofi or AstraZeneca?
Sanofi is more profitable, with an operating margin of 30.1% against 27.1%.
More: Sanofi earnings · how Sanofi makes money · AstraZeneca earnings · how AstraZeneca makes money
From the companies' latest 10-Q, 10-K or earnings release (6-K filed Oct 30, 2026; 6-K filed Oct 30, 2026). Fiscal quarters can end on different dates. Not investment advice.